Eli Lilly and Company (NYSE: LLY) has a market capitalization of approximately $947 billion as of February 2026. The Indianapolis-based drugmaker, founded in 1876, ranks among the world's most valuable pharmaceutical companies, driven largely by its GLP-1 portfolio including Mounjaro and Zepbound.
Earnings of Eli Lilly
Annual Earnings of Eli Lilly
| Year | Net Income (USD) | Change | Growth |
|---|---|---|---|
| 2025 | $20.64B | +$10.05B | +94.90% |
| 2024 | $10.59B | +$5.35B | +102.10% |
| 2023 | $5.24B | -$1.00B | -16.08% |
| 2022 | $6.24B | +$0.66B | +11.88% |
| 2021 | $5.58B | +$1.31B | +30.68% |
| 2020 | $4.27B | -$4.05B | -48.68% |
| 2019 | $8.32B | +$5.58B | +203.65% |
| 2018 | $2.74B | +$2.94B | N/A |
| 2017 | -$0.20B | -$2.94B | -107.30% |
| 2016 | $2.74B | +$0.33B | +13.69% |
Eli Lilly P/E Ratio
| Year | P/E Ratio | Change |
|---|---|---|
| 2025 | 46.76 | -28.78% |
| 2024 | 65.65 | -34.38% |
| 2023 | 100.04 | +79.72% |
| 2022 | 55.66 | +17.95% |
| 2021 | 47.19 | +80.98% |
| 2020 | 26.08 | +72.36% |
| 2019 | 15.13 | -58.89% |
| 2018 | 36.80 | N/A |
| 2017 | -435.34 | N/A |
| 2016 | 29.58 | -23.51% |